SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation

The Company previously announced positive interim results from the trial meeting its primary endpoints TEL AVIV, Israel, May 02, 2023 -- SciSparc Ltd. , a specialty clinical-stage pharmaceutical... | May 2, 2023

Related Keywords

Israel ,Israeli ,Alexander Kaplan ,Exchange Commission ,Company Phase Iia ,Company Or Scisparc ,Israeli Medical Center ,Scisparc Ltd ,Nasdaq ,Cohen Mansfield Agitation Inventory ,Edinburgh Feeding Evaluation ,Mini Mental State Exam ,Disease Assessment Scale Cognitive ,Pittsburgh Sleep Quality Index ,Open Label Trial ,Efficacy Trend ,Tourette Syndrome ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Scisparc Stock Exchange ,News ,Information ,Press Release ,The ,Company ,Reviously ,Nnounced ,Positive ,Interim ,Results ,Rom ,Trial ,Meeting ,Its ,Primary ,Endpoints ,El ,Bay ,023 ,Scisparc ,Pecialty Sprc Il0010951403 ,